Combination treatment with TS-1+CDDP+Trastuzumab for unresectable HER 2 positive gastric cancer (A Phase II Study)
Phase 2
- Conditions
- nresectable HER2 positive gastric cancer
- Registration Number
- JPRN-UMIN000005876
- Lead Sponsor
- Toho University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. patient who has drug allergy as past history 2. patient who needs flucytosine, phenytoin, and Warfarin 3. patient who has active infectious disease with fever over 38 degree 4. patient who has severe complication (interstitial pneumonia, DM, renal failure, liver failure under bad control) 5. watery diarrhea 6. Pleural effusion and acites 7. patient who has heart disease(CHF, old MI, IHD, arrhythmia, and a valvular disease of the heart) 8.Uncontrolable hypertention 9. patient who has active double cancer 10. patient who want to be pregnant and /or pregnant woman 11. man who want to have a child 12. patient who was judged to be unsuitable for this clinical trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Antitumor efficacy
- Secondary Outcome Measures
Name Time Method Progression-free survival (PFS) Overall survival (OS) Antitumor efficacy Adverse events